The Effect of Oral Iptacopan Monotherapy on Hematological Parameters in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) is Consistent Regardless of the Type of Prior Anti-C5 Treatment Received: A Post Hoc Analysis of 24-Week Data from the Randomized Phase III APPLY-PNH Trial

Poster Presentation
© 2024 American Society of Hematology. All rights reserved.
Meeting: 2024 ASH® Annual Meeting
Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Presenter: Regis Peffault De Latour
Affiliation: rench Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Saint-Louis Hospital, Paris, France; Université Paris Cité, Paris, France; The Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation, Barcelona, Spain
Presentation Date: December 9, 2024
Abstract Number: 4087
Session: Session: 508. Bone Marrow Failure: Acquired: Poster III
Related content: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Poster Presentation
Abstract Number: 2327
Presenter: David Dingli, MD, PhD
Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Date Presented: December 7, 2024
Poster Presentation
Abstract Number: 5012
Presenter: Shreyans Gandhi, MD, MBBS, DNB, FRCPath, MPhil, MRCP
Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Date Presented: December 9, 2024

To access this content please accept the following declarations.

This content was selected by and is provided to you upon your unsolicited request courtesy of Novartis with permission of ASH®.